A therapeutic cancer vaccine designed to evoke an immune response to human chorionic gonadotropin. While it made it to clinical trials for treating colorectal, pancreatic and prostate cancers, it proved ineffective and has been discontinued.
has announced that its therapeutic cancer vaccine, AVICINE, provided a substantial survival benefit in patients with pancreatic cancer.
In a 55-patient Phase II study, patients were treated with AVICINE alone or in combination with gemcitabine (Gemzar(R), Eli Lilly & Co.
One-year survival data for the AVICINE alone group is similar to that reported for Gemzar.
The findings provide ample support for AVI's ongoing AVICINE cancer vaccine program.
Our preliminary data, presented at the annual meeting of the American Society of Oncology (ASCO) in May, 2001, suggested that AVICINE is as effective as traditional chemotherapy, but without the devastating side effects associated with that treatment," said David H.